GKOS

+ Watchlist + Portfolio

Glaukos Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $189.55
52-Week Range: $73.16 – $191.62
Market Cap: $10.91B
P/E (TTM): —
EPS (TTM): -3.20
Dividend Yield: —

Advanced Metrics

Price/Book: 15.95
PEG Ratio: —
Return on Equity: -25.98%
Return on Assets: -5.18%
Gross Margin: 79.12%
Operating Margin: -8.49%
Profit Margin: -30.69%
Current Ratio: 5.04
Debt/Equity: 0.16
Total Debt: $107.60M
Free Cash Flow: $15.46M
Revenue Growth: 49.50%
Earnings Growth: —
Enterprise Value: $10.72B

GKOS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$282.86M	$314.71M	$383.48M	$507.44M
Cost of Revenue	$68.98M	$75.58M	$94.03M	$224.68M
Gross Profit	$213.88M	$239.14M	$289.45M	$282.76M
Research & Development	$123.27M	$138.77M	$136.43M	$150.61M
Selling, General & Admin	$192.93M	$224.07M	$261.17M	$331.75M
Operating Expenses	$316.20M	$362.84M	$397.59M	$482.36M
Operating Income	-$102.31M	-$123.70M	-$108.14M	-$199.60M
EBITDA	-$48.76M	-$82.12M	-$95.64M	-$146.06M
Pretax Income	-$98.43M	-$133.73M	-$145.60M	-$193.04M
Income Tax	$766.00K	$934.00K	$771.00K	-$5.35M
Net Income	-$99.19M	-$134.66M	-$146.37M	-$187.69M
Diluted EPS	-2.09	-2.78	-2.77	-3.28
Diluted Shares	47.44M	48.43M	52.76M	57.19M

GKOS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$119.53M	$93.47M	$169.63M	$90.81M
Receivables	$36.07M	$39.85M	$60.74M	$108.61M
Inventory	$37.84M	$41.99M	$57.68M	$63.56M
Current Assets	$443.86M	$395.46M	$449.79M	$474.98M
Total Assets	$1.00B	$940.41M	$974.76M	$893.49M
Current Liabilities	$72.36M	$74.01M	$75.13M	$101.28M
Long-Term Debt	$281.40M	$282.77M	—	—
Total Debt	$382.48M	$383.74M	$103.40M	$103.88M
Total Liabilities	$472.38M	$478.65M	$207.82M	$237.33M
Retained Earnings	-$464.41M	-$599.07M	-$745.44M	-$933.13M
Shareholders' Equity	$530.00M	$461.77M	$766.93M	$656.15M
Working Capital	$371.50M	$321.45M	$374.67M	$373.71M
Net Debt	$161.88M	$189.31M	—	—

GKOS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$33.08M	-$57.76M	-$61.32M	-$14.79M
Capital Expenditure	-$30.27M	-$20.25M	-$6.30M	-$24.27M
Free Cash Flow	-$63.35M	-$78.01M	-$67.62M	-$39.06M
Depreciation & Amortisation	$35.95M	$37.98M	$39.92M	$42.34M
Stock-Based Compensation	$38.56M	$43.53M	$50.21M	$63.22M
Investing Cash Flow	$44.78M	$14.10M	$47.83M	-$77.61M
Financing Cash Flow	$6.25M	$15.04M	$91.54M	$11.89M
Net Change in Cash	$17.95M	-$28.62M	$78.05M	-$80.52M

GKOS Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$124.12M	$133.54M	$143.12M	$150.57M	$185.61M
Cost of Revenue	$26.90M	$28.83M	$144.64M	$33.34M	$34.02M
Gross Profit	$97.22M	$104.71M	-$1.52M	$117.23M	$151.59M
Research & Development	$36.54M	$38.07M	$43.65M	$44.15M	$51.30M
Selling, General & Admin	$83.38M	$83.00M	$94.70M	$92.94M	$116.06M
Operating Expenses	$119.91M	$121.07M	$138.35M	$137.09M	$167.36M
Operating Income	-$22.69M	-$16.36M	-$139.87M	-$19.86M	-$15.77M
EBITDA	-$8.63M	-$4.63M	-$125.44M	-$5.29M	-$6.12M
Pretax Income	-$19.41M	-$16.00M	-$139.82M	-$19.30M	-$17.72M
Income Tax	$248.00K	$234.00K	-$6.16M	$484.00K	$656.00K
Net Income	-$19.66M	-$16.23M	-$133.66M	-$19.78M	-$18.38M
Diluted EPS	-0.34	-0.28	-2.32	-0.34	-0.31
Diluted Shares	57.20M	57.40M	57.51M	58.02M	58.82M

GKOS Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$100.81M	$98.25M	$90.81M	$104.25M	$114.48M
Receivables	$82.98M	$98.68M	$108.61M	$119.69M	$138.90M
Inventory	$64.62M	$63.86M	$63.56M	$62.38M	$59.31M
Current Assets	$436.06M	$454.77M	$474.98M	$485.75M	$515.78M
Total Assets	$986.96M	$999.38M	$893.49M	$893.33M	$920.52M
Current Liabilities	$79.14M	$87.52M	$101.28M	$89.42M	$102.33M
Total Debt	$105.02M	$104.31M	$103.88M	$103.06M	$102.84M
Total Liabilities	$221.85M	$229.84M	$237.33M	$222.40M	$238.03M
Retained Earnings	-$783.24M	-$799.47M	-$933.13M	-$952.91M	-$971.29M
Shareholders' Equity	$765.11M	$769.54M	$656.15M	$670.93M	$682.49M
Working Capital	$356.93M	$367.25M	$373.71M	$396.34M	$413.45M

GKOS Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$6.98M	-$10.09M	$6.84M	-$12.53M	$14.82M
Capital Expenditure	-$1.18M	-$1.64M	-$19.52M	-$3.96M	-$2.74M
Free Cash Flow	$5.80M	-$11.72M	-$12.68M	-$16.48M	$12.09M
Depreciation & Amortisation	$9.62M	$10.19M	$13.23M	$12.88M	$10.14M
Stock-Based Compensation	$18.02M	$14.91M	$17.30M	$19.14M	$28.86M
Investing Cash Flow	-$20.78M	-$3.99M	-$15.89M	$10.50M	-$5.31M
Financing Cash Flow	$2.25M	$5.26M	$2.43M	$15.77M	$991.00K
Net Change in Cash	-$11.56M	-$8.82M	-$6.62M	$13.75M	$10.51M

Market Snapshot

About

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing treatments for glaucoma, corneal disorders, and retinal diseases. The company's flagship product line includes micro-invasive glaucoma surgery (MIGS) devices designed to reduce intraocular pressure in glaucoma patients. Glaukos also develops pharmaceutical therapies and innovative surgical devices for various eye conditions. The company serves ophthalmologists and eye care professionals worldwide, competing in the growing market for minimally invasive eye disease treatments.